Eisai Co., Ltd.: Carcinoma, Hepatocellular trials

The registry lists 20 Carcinoma, Hepatocellular studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 10Phase 2 6Phase 3 2Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results posted
• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaCompletedNCT01761266Phase 3Results posted
• E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular CarcinomaCompletedNCT01271504Phase 1/2Results posted
• Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00946153Phase 1/2Results posted
• Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)Active, not recruitingNCT07849660
• A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) ParticipantsCompletedNCT05225207
• A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular CarcinomaCompletedNCT04763408
• A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCCCompletedNCT04297254Phase 4
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Phase 1/2
• A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT04008082
• A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 1
• A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT03663114
• Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruitingNCT03264664Phase 1
• Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
• Post-marketing Surveillance of DC Bead in Patients With Hepatocellular CarcinomaCompletedNCT02269995
• A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular CarcinomaTerminatedNCT00165633Phase 2/3